Free Trial
NASDAQ:JANX

Janux Therapeutics Q1 2025 Earnings Report

Janux Therapeutics logo
$29.06 +0.11 (+0.38%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$25.64 -3.42 (-11.75%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Janux Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.42
Beat/Miss
N/A
One Year Ago EPS
N/A

Janux Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.59 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Janux Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, May 6, 2025
Conference Call Time
11:00AM ET

Conference Call Resources

Remove Ads

Janux Therapeutics Earnings Headlines

Janux Therapeutics: What's My Inflection Point?
Janux Therapeutics: What's My Inflection Point?
Two Unmistakable Patterns Return…
The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at record pace. Why massive amounts of gold are being moved between countries. Why governments are repositioning their gold reserves. But here's what most people miss, the second pattern: During these resets, a unique anomaly appears in certain gold mining stocks. I call it the "Golden Anomaly."
10 Best Small-Cap Stocks to Buy Before They Explode
See More Janux Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Janux Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Janux Therapeutics and other key companies, straight to your email.

About Janux Therapeutics

Janux Therapeutics (NASDAQ:JANX), a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

View Janux Therapeutics Profile

More Earnings Resources from MarketBeat